Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections

scientific article

Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/340365
P698PubMed publication ID12001037
P5875ResearchGate publication ID11369952

P50authorAlan L. RothmanQ37367924
Siripen KalayanaroojQ60059354
Ananda NisalakQ60059374
Timothy P EndyQ90780747
Sharone GreenQ101978812
Daniel H LibratyQ115301439
Francis A EnnisQ115301446
P2093author name stringDavid W Vaughn
Huo-Shu H Houng
Saroj Suntayakorn
Wanya Chansiriwongs
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectvirusQ808
Dengue virusQ476209
P304page(s)1213-1221
P577publication date2002-04-16
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleDiffering influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections
P478volume185

Reverse relations

cites work (P2860)
Q40546528A Blunted Blood Plasmacytoid Dendritic Cell Response to an Acute Systemic Viral Infection Is Associated with Increased Disease Severity
Q27486786A Mouse-Passaged Dengue Virus Strain with Reduced Affinity for Heparan Sulfate Causes Severe Disease in Mice by Establishing Increased Systemic Viral Loads
Q27490166A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model
Q34309568A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro
Q24276108A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease
Q27305445A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-γ in host resistance to infection
Q38884987A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection
Q34288828A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients
Q39847833A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells
Q35082478A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture
Q34009510A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection
Q35727211Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection
Q33774668Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production
Q34359759Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses
Q27473379American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells
Q43046621An IRF-3-, IRF-5-, and IRF-7-Independent Pathway of Dengue Viral Resistance Utilizes IRF-1 to Stimulate Type I and II Interferon Responses
Q34353489An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection.
Q96131739Analysis of cell-associated DENV RNA by oligo(dT) primed 5' capture scRNAseq
Q90167450Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection
Q25708015Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses
Q27485451Antibody-Dependent Enhancement of Hepatitis C Virus Infection
Q36628520Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy
Q40340416Association of Intracellular TH1-TH2 Balance in CD4+ T-cells and MIP-1α in CD8+ T-cells with Disease Severity in Adults with Dengue
Q33363392Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections
Q33785818Both Viremia and Cytokine Levels Associate with the Lack of Severe Disease in Secondary Dengue 1 Infection among Adult Chinese Patients
Q33696548Bystander T cells in human immune responses to dengue antigens
Q55261090Calling in sick: impacts of fever on intra-urban human mobility.
Q40061338Case Management of Dengue: Lessons Learned
Q37372604Characteristics of mild dengue virus infection in Thai children
Q52646073Characterization of a murine model of non-lethal, symptomatic dengue virus infection
Q27487088Chikungunya Fever in Travelers Returning to Europe from the Indian Ocean Region, 2006
Q41928393Chymase is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients
Q28551786Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes
Q27490805Clinical Findings and Pro-Inflammatory Cytokines in Dengue Patients in Western India: A Facility-Based Study
Q33757489Clinical and virological characteristics of dengue in Surabaya, Indonesia
Q35954329Clinical evaluation of dengue and identification of risk factors for severe disease: protocol for a multicentre study in 8 countries
Q37540534Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression
Q40432727Computational prediction and identification of dengue virus-specific CD4(+) T-cell epitopes
Q91807708Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention
Q38016235Controversies in dengue pathogenesis
Q35071222Corticosteroids for dengue - why don't they work?
Q33415746Corticosteroids in the treatment of dengue shock syndrome
Q40130106Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?
Q36853974Coupled Heterogeneities and Their Impact on Parasite Transmission and Control
Q37907783Critical issues in dengue vaccine development
Q35551374Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans
Q102372418Current Understanding of the Pathogenesis of Dengue Virus Infection
Q85389327Defeating dengue: a challenge for a vaccine
Q44170267Definitive tests for dengue fever: when and which should I use?
Q34722528Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity
Q29619772Dengue
Q39371396Dengue Hemorrhagic Fever: A State-of-the-Art Review Focused in Pulmonary Involvement
Q27491350Dengue Hemorrhagic Fever: The Sensitivity and Specificity of the World Health Organization Definition for Identification of Severe Cases of Dengue in Thailand, 1994–2005
Q36745257Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection
Q27481002Dengue Virus Detection Using Whole Blood for Reverse Transcriptase PCR and Virus Isolation
Q35641205Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
Q37547790Dengue Virus Serotypes Circulating in Khyber Pakhtunkhwa Province, Pakistan, 2013-2015
Q35865823Dengue and Soluble Mediators of the Innate Immune System
Q90825369Dengue drug discovery: Progress, challenges and outlook
Q40114849Dengue epidemics in two distinct periods reveal distinct epidemiological, laboratorial and clinical aspects in a same scenario: analysis of the 2010 and 2013 epidemics in Mato Grosso do Sul, Brazil
Q30245613Dengue fever virus in Pakistan: effects of seasonal pattern and temperature change on distribution of vector and virus
Q24803937Dengue fever: new paradigms for a changing epidemiology
Q35739855Dengue hemorrhagic fever-associated immunomediators induced via maturation of dengue virus nonstructural 4B protein in monocytes modulate endothelial cell adhesion molecules and human microvascular endothelial cells permeability
Q39590469Dengue human infection models supporting drug development
Q43047774Dengue immune response: low affinity, high febrility
Q27489388Dengue in Vietnamese Infants—Results of Infection‐Enhancement Assays Correlate with Age‐Related Disease Epidemiology, and Cellular Immune Responses Correlate with Disease Severity
Q34766802Dengue in travelers: kinetics of viremia and NS1 antigenemia and their associations with clinical parameters
Q47562022Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies
Q37868122Dengue vaccines: progress and challenges
Q34531786Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status
Q34118200Dengue virus
Q31110897Dengue virus NS1 enhances viral replication and pro-inflammatory cytokine production in human dendritic cells
Q35002940Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation.
Q40198181Dengue virus and host antibody: a dangerous balancing act.
Q37436763Dengue virus infection differentially regulates endothelial barrier function over time through type I interferon effects
Q34364315Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells
Q38933520Dengue virus infection of erythroid precursor cells is modulated by both thalassemia trait status and virus adaptation
Q27470758Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion
Q24645380Dengue virus pathogenesis: an integrated view
Q35119732Dengue virus type 2 (DENV2)-induced oxidative responses in monocytes from glucose-6-phosphate dehydrogenase (G6PD)-deficient and G6PD normal subjects
Q27026302Dengue viruses - an overview
Q35276730Dengue--quo tu et quo vadis?
Q28085044Dengue: an update on treatment options
Q24609884Dengue: defining protective versus pathologic immunity
Q42995650Dengue: translating scientific progress into workable solutions
Q35896391Dengue: where are we today?
Q39004916Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control
Q34834135Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection
Q64099613Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines
Q40345145Development and evaluation of a fluorogenic real‐time RT‐PCR for the detection of dengue 3 virus
Q27491049Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys
Q27488073Development of real time PCR for detection and quantitation of dengue viruses
Q27487547Diagnostic Accuracy of NS1 ELISA and Lateral Flow Rapid Tests for Dengue Sensitivity, Specificity and Relationship to Viraemia and Antibody Responses
Q91927668Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
Q27485627Differential Gene Expression Changes in Children with Severe Dengue Virus Infections
Q40516020Differential effects of dengue virus on infected and bystander dendritic cells
Q35130239Differential susceptibility of two field aedes aegypti populations to a low infectious dose of dengue virus
Q24318532Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection
Q35922064Distribution of Dengue Virus Types 1 and 4 in Blood Components from Infected Blood Donors from Puerto Rico
Q37682895Domain III of the envelope protein as a dengue vaccine target
Q27882968Drivers of Inter-individual Variation in Dengue Viral Load Dynamics
Q38256785Drugs for dengue: a patent review (2010-2014).
Q27469477Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections
Q33402687Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial
Q34630222Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti
Q27485633Elevated levels of soluble ST2 protein in dengue virus infected patients
Q36146301Elevated levels of vitamin D and deficiency of mannose binding lectin in dengue hemorrhagic fever
Q33926902Endemic dengue associated with the co-circulation of multiple viral lineages and localized density-dependent transmission
Q26825663Endothelial cells in dengue hemorrhagic fever
Q40294304Enhanced humoral and HLA‐A2‐restricted dengue virus‐specific T‐cell responses in humanized BLT NSG mice
Q29196526Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity
Q34448752Evaluation of dengue NS1 antigen rapid tests and ELISA kits using clinical samples
Q34761908Evaluation of host and viral factors associated with severe dengue based on the 2009 WHO classification
Q33609685Evasion of the human innate immune system by dengue virus
Q39565102Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus
Q34531142Factors Influencing Dengue Virus Isolation by C6/36 Cell Culture and Mosquito Inoculation of Nested PCR-Positive Clinical Samples
Q31156754First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies
Q28943386Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1
Q28073351Genomic approaches for understanding dengue: insights from the virus, vector, and host
Q41929035Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response
Q43239729Glucocorticosteroids as Dengue Therapeutics: Resolving Clinical Observations With a Primary Human Macrophage Model
Q42652891Halogenated Chrysins Inhibit Dengue and Zika Virus Infectivity
Q33419779High producing tumor necrosis factor alpha gene alleles in protection against severe manifestations of dengue
Q40147299Higher levels of dengue-virus-specific IgG and IgA during pre-defervescence associated with primary dengue hemorrhagic fever
Q34580259Highly conserved residues in the helical domain of dengue virus type 1 precursor membrane protein are involved in assembly, precursor membrane (prM) protein cleavage, and entry
Q37793734How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections
Q95819383Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections
Q40341498Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes
Q26314609Human antibody response to dengue virus: implications for dengue vaccine design
Q25161212Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus
Q33418083Hyperferritinaemia in dengue virus infected patients is associated with immune activation and coagulation disturbances
Q40042448IL-10 and socs3 Are Predictive Biomarkers of Dengue Hemorrhagic Fever
Q39372304IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba
Q35807844Identification of clinical factors associated with severe dengue among Thai adults: a prospective study
Q39781949Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate
Q33438726IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity
Q27490592Immature Dengue Virus: A Veiled Pathogen?
Q33430763Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India--Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity
Q39236667Immune-mediated cytokine storm and its role in severe dengue
Q37901360Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms
Q34642396Immunocapture couples with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for rapid detection of type 1 dengue virus
Q34165624Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.
Q33841915Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam.
Q35613349Immunology and immunopathogenesis of dengue disease
Q39410861Immunopathogenesis Versus Protection in Dengue Virus Infections
Q38157106Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques
Q30250977In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
Q33928921Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function
Q40233196Increased production of interleukin-4, interleukin-10, and granulocyte-macrophage colony-stimulating factor by type 2 diabetes' mononuclear cells infected with dengue virus, but not increased intracellular viral multiplication.
Q40307795Infection and activation of human peripheral blood monocytes by dengue viruses through the mechanism of antibody-dependent enhancement.
Q27485321Infection-Enhancing and -Neutralizing Activities of Mouse Monoclonal Antibodies against Dengue Type 2 and 4 Viruses Are Controlled by Complement Levels
Q40480637Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).
Q36619335Insights into the molecular evolution of Dengue virus type 4 in Puerto Rico over two decades of emergence
Q33962671Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever.
Q35804633Into the eye of the cytokine storm
Q40331473Intracerebral infection with dengue-3 virus induces meningoencephalitis and behavioral changes that precede lethality in mice
Q34671059Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes
Q38870485Investigational drugs in early development for treating dengue infection.
Q30395396Issues Related to Recent Dengue Vaccine Development
Q36166556Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults
Q38618056Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?
Q33394239Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status
Q28476805Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue
Q37599913Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue
Q36396156Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo
Q36497872Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial
Q24570135Maturation of dengue virus nonstructural protein 4B in monocytes enhances production of dengue hemorrhagic fever-associated chemokines and cytokines
Q34088956Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive
Q41722923Meta-analysis of biomarkers for severe dengue infections.
Q34746720Microbial translocation is associated with extensive immune activation in dengue virus infected patients with severe disease
Q28742358Microevolution and virulence of dengue viruses
Q35009344Minimal within-host dengue models highlight the specific roles of the immune response in primary and secondary dengue infections
Q35082837Models of the impact of dengue vaccines: a review of current research and potential approaches
Q33401149Mosquito Bite Delivery of Dengue Virus Enhances Immunogenicity and Pathogenesis in Humanized Mice
Q24276139Mouse models of dengue virus infection for vaccine testing
Q27010151Mouse models to study dengue virus immunology and pathogenesis
Q27486434Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity
Q55648073NS1 Antigenemia and Viraemia Load: Potential Markers of Progression to Dengue Fatal Outcome?
Q37884400NS3 protease from flavivirus as a target for designing antiviral inhibitors against dengue virus
Q38646923New insights into the immunopathology and control of dengue virus infection
Q34583461Novel Benzoxazole Inhibitor of Dengue Virus Replication That Targets the NS3 Helicase
Q38636217Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development
Q58997716Pathogenesis of Dengue Haemorrhagic Fever and Its Impact on Case Management
Q26766198Pathogenesis of Dengue: Dawn of a New Era
Q35097474Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection
Q33702837Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever
Q33436206Peptide Bbeta(15-42) preserves endothelial barrier function in shock
Q39017020Peptide inhibitors against dengue virus infection.
Q39835610Phenotypic analysis of dengue virus isolates associated with dengue fever and dengue hemorrhagic fever for cellular attachment, replication and interferon signaling ability
Q50255448Plasma leakage in dengue haemorrhagic fever
Q21146686Predicting outcome from dengue
Q37007528Primary dengue haemorrhagic fever in patients from northeast of Brazil is associated with high levels of interferon-β during acute phase
Q34345965Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans
Q34054616Progress in the identification of dengue virus entry/fusion inhibitors
Q27472702Randomized, Placebo-Controlled Trial of Nonpegylated and Pegylated Forms of Recombinant Human Alpha Interferon 2a for Suppression of Dengue Virus Viremia in Rhesus Monkeys
Q27477646Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis
Q26766156Recent advances in understanding dengue
Q92859173Recent advances in understanding dengue
Q39187784Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design
Q40293933Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice
Q27469474Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
Q37390846Reverse transcription loop-mediated isothermal amplification (RT-LAMP) for diagnosis of dengue
Q33440083Risk factors and clinical outcome of profound thrombocytopenia in adult patients with DENV infections
Q92392677Role of microRNAs in antiviral responses to dengue infection
Q45017668Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.
Q36382589Sculpting humoral immunity through dengue vaccination to enhance protective immunity
Q24558700Selection for virulent dengue viruses occurs in humans and mosquitoes
Q35250382Sensitivity and specificity of a novel classifier for the early diagnosis of dengue
Q34855189Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity
Q39302764Serological characterization of dengue virus infections observed among dengue hemorrhagic fever/dengue shock syndrome cases in upper Myanmar
Q97549435Serum chymase levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients
Q40161217Serum levels of IL-8, IFNγ, IL-10, and TGF β and their gene expression levels in severe and non-severe cases of dengue virus infection
Q40469577Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever.
Q27487319Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages
Q38023832Staphylococcus aureus pneumonia and dengue virus co-infection and review of implications of coinfection
Q27491097Sylvatic Dengue Viruses Share the Pathogenic Potential of Urban/Endemic Dengue Viruses
Q63246534T-Cell Response to Viral Hemorrhagic Fevers
Q27485295TRAIL Is a Novel Antiviral Protein against Dengue Virus
Q56916580The Battle between Infection and Host Immune Responses of Dengue Virus and Its Implication in Dengue Disease Pathogenesis
Q33817714The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection
Q35594746The burden of dengue and chikungunya worldwide: implications for the southern United States and California
Q37903445The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
Q34903764The history and evolution of human dengue emergence
Q36132065The impact of transgenic mosquitoes on dengue virulence to humans and mosquitoes
Q37904027The pathogenesis of dengue
Q37713190The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome
Q34431491Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials
Q33389673Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue
Q92119078Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection
Q50117666Transcytosis Involvement in Transport System and Endothelial Permeability of Vascular Leakage during Dengue Virus Infection
Q55333503Transmission-clearance trade-offs indicate that dengue virulence evolution depends on epidemiological context.
Q57061707Use of structural equation models to predict dengue illness phenotype
Q65054977Using Macaques to Address Critical Questions in Zika Virus Research.
Q37330748Vaccine-induced enhancement of viral infections.
Q33413903Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses
Q40167695Vascular leakage in dengue hemorrhagic Fever is associated with dengue infected monocytes, monocyte activation/exhaustion, and cytokines production
Q27478050Virus-Induced Decline in Soluble Vascular Endothelial Growth Receptor 2 Is Associated with Plasma Leakage in Dengue Hemorrhagic Fever

Search more.